Brought to you by 
MediStem gets IP from Yale University for use in cell therapies for Type I diabetes
14 Mar 2012
Executive Summary
Stem cell company MediStem Inc. has received exclusive worldwide rights to Yale University's IP for use in developing pancreatic islets from stem cells such as endometrial regenerative cells (ERCs).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MediStem gets IP from Yale University for use in cell therapies for Type I diabetes
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice